24 May 2013 - AbbVie, a company that solves complex health issues and brings scientific discoveries to market, has started a Phase three study of atrasentan on renal outcomes including the onset of end-stage renal disease, transplant or death due to renal failure progression in patients with diabetic nephropathy.

It was reported yesterday that the study would evaluate the effects of atrasentan upon addition to standard of care on progression of kidney disease in patients with stage two to four chronic kidney disease and type 2 diabetes.

The company is enrolling more than 4,000 patients with diabetic nephropathy in the multinational, double blind, placebo-controlled study.